Favaloro Emmanuel J, Mohammed Soma
Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Pathology West, Westmead Hospital, Westmead, NSW, Australia.
Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Pathology West, Westmead Hospital, Westmead, NSW, Australia.
Thromb Res. 2014 Dec;134(6):1292-300. doi: 10.1016/j.thromres.2014.09.024. Epub 2014 Sep 28.
von Willebrand disease (VWD) is reportedly the most common bleeding disorder and arises from deficiency and/or defects of von Willebrand factor (VWF). Laboratory diagnosis and typing has important management implications and requires a wide range of tests, including VWF activity and antigen, and involves differential identification of qualitative vs quantitative defects.
We have assessed several VWF antigen and activity assays (collagen binding [VWF:CB], ristocetin cofactor [VWF:RCo] and the new Siemens INNOVANCE assay [VWF:Ac], employing latex particles and gain of function recombinant glycoprotein Ib to facilitate VWF binding and agglutination without need for ristocetin) using different instrumentation, including the new Sysmex CS-5100, with a large sample test set (n=600). We included retrospective plus prospective study designs, and also evaluated desmopressin responsiveness plus differential sensitivity to high molecular weight VWF.
VWF:Ag and VWF:RCo results from different methods were respectively largely comparable, although some notable differences were evident, including one high false normal VWF:Ag value (105 U/dL) on a type 3 VWD sample, possibly due to heterophile antibody interference in the latex-based CS-5100 methodology. VWF:Ac was largely comparable to VWF:RCo, but VWF:CB showed discrepant findings to both VWF:RCo and VWF:Ac with some patients, most notably patients with type 2M VWD.
(a) VWF:Ag on different platforms are largely interchangeable, as are VWF:RCo on different platforms, except for occasional (some potentially important) differences, and manufacturer recommended methods may otherwise require some assay optimization; (b) VWF:RCo and VWF:Ac are largely interchangeable, except for occasional differences that may also relate to assay design (differing optimizations); (c) VWF:CB provides an additional activity to supplement VWF:RCo or VWF:Ac activity assays, and is not interchangeable with either.
据报道,血管性血友病(VWD)是最常见的出血性疾病,由血管性血友病因子(VWF)缺乏和/或缺陷引起。实验室诊断和分型对治疗管理具有重要意义,需要进行多种检测,包括VWF活性和抗原检测,并涉及定性与定量缺陷的鉴别诊断。
我们使用不同仪器,包括新型Sysmex CS - 5100,对多个VWF抗原和活性检测方法(胶原结合法[VWF:CB]、瑞斯托霉素辅因子法[VWF:RCo]以及新型西门子INNOVANCE检测法[VWF:Ac],该方法采用乳胶颗粒和功能增强的重组糖蛋白Ib来促进VWF结合和凝集,无需瑞斯托霉素)进行了评估,样本量较大(n = 600)。我们采用了回顾性和前瞻性研究设计,还评估了去氨加压素反应性以及对高分子量VWF的差异敏感性。
不同方法检测的VWF:Ag和VWF:RCo结果总体上具有可比性,尽管存在一些显著差异,包括1例3型VWD样本出现一个较高的假正常VWF:Ag值(105 U/dL),这可能是由于基于乳胶的CS - 5100方法中存在嗜异性抗体干扰。VWF:Ac与VWF:RCo总体上具有可比性,但VWF:CB在一些患者中,尤其是2M型VWD患者中,与VWF:RCo和VWF:Ac的结果存在差异。
(a)不同平台上的VWF:Ag在很大程度上可相互替代,不同平台上的VWF:RCo也是如此,除了偶尔出现的(一些可能很重要的)差异,否则制造商推荐的方法可能需要进行一些检测优化;(b)VWF:RCo和VWF:Ac在很大程度上可相互替代,除了偶尔出现的差异,这些差异也可能与检测设计(不同的优化)有关;(c)VWF:CB提供了一种补充VWF:RCo或VWF:Ac活性检测的额外活性检测方法,且与两者均不可相互替代。